Self-reported symptoms among participants in a population-based screening program.


Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 12 06 2020
revised: 21 08 2020
accepted: 24 08 2020
pubmed: 15 9 2020
medline: 4 8 2021
entrez: 14 9 2020
Statut: ppublish

Résumé

A limited number of studies have explored the association between self-reported symptoms and the risk of breast cancer among participants of population based screening programs. We performed descriptive statistics on recall, screen-detected and interval cancer, positive predictive value and histopathological tumour characteristics by symptom group (asymptomatic, lump, and skin or nipple changes) as reported from 785,642 women aged 50-69 when they attended BreastScreen Norway 1996-2016. Uni- and multivariable mixed effects logistic regression models were used to analyze the association between symptom group and screen-detected or interval cancer. Results were presented as odds ratios and 95% confidence intervals (CI). A lump or skin/nipple change was reported in 6.2% of the 3,307,697 examinations. The rate of screen-detected cancers per 1000 examinations was 45.2 among women with a self-reported lump and 5.1 among asymptomatic women. Adjusted odds ratio of screen-detected cancer was 10.1 (95% CI: 9.3-11.1) and 2.0 (95% CI: 1.6-2.5) for interval cancer among women with a self-reported lump versus asymptomatic women. Tumour diameter, histologic grade and lymph node involvement of screen-detected and interval cancer were less prognostically favourable for women with a self-reported lump versus asymptomatic women. Despite targeting asymptomatic women, 6.2% of the screening examinations in BreastScreen Norway was performed among women who reported a lump or skin/nipple change when they attended screening. The odds ratio of screen-detected cancer was higher for women with versus without symptoms. Standardized follow-up guidelines might be beneficial for screening programs in order to take care of women reporting signs or symptoms of breast cancer when they attend screening.

Sections du résumé

BACKGROUND BACKGROUND
A limited number of studies have explored the association between self-reported symptoms and the risk of breast cancer among participants of population based screening programs.
METHODS METHODS
We performed descriptive statistics on recall, screen-detected and interval cancer, positive predictive value and histopathological tumour characteristics by symptom group (asymptomatic, lump, and skin or nipple changes) as reported from 785,642 women aged 50-69 when they attended BreastScreen Norway 1996-2016. Uni- and multivariable mixed effects logistic regression models were used to analyze the association between symptom group and screen-detected or interval cancer. Results were presented as odds ratios and 95% confidence intervals (CI).
RESULTS RESULTS
A lump or skin/nipple change was reported in 6.2% of the 3,307,697 examinations. The rate of screen-detected cancers per 1000 examinations was 45.2 among women with a self-reported lump and 5.1 among asymptomatic women. Adjusted odds ratio of screen-detected cancer was 10.1 (95% CI: 9.3-11.1) and 2.0 (95% CI: 1.6-2.5) for interval cancer among women with a self-reported lump versus asymptomatic women. Tumour diameter, histologic grade and lymph node involvement of screen-detected and interval cancer were less prognostically favourable for women with a self-reported lump versus asymptomatic women.
CONCLUSION CONCLUSIONS
Despite targeting asymptomatic women, 6.2% of the screening examinations in BreastScreen Norway was performed among women who reported a lump or skin/nipple change when they attended screening. The odds ratio of screen-detected cancer was higher for women with versus without symptoms. Standardized follow-up guidelines might be beneficial for screening programs in order to take care of women reporting signs or symptoms of breast cancer when they attend screening.

Identifiants

pubmed: 32927237
pii: S0960-9776(20)30168-5
doi: 10.1016/j.breast.2020.08.015
pmc: PMC7495098
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-61

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Cancer. 2011 Apr 1;117(7):1360-8
pubmed: 21425135
Int J Cancer. 2015 Mar 15;136(6):E630-7
pubmed: 25160029
Br J Cancer. 2018 Nov;119(11):1428-1435
pubmed: 30401890
BMC Cancer. 2013 Jan 10;13:15
pubmed: 23305429
PLoS One. 2019 Dec 16;14(12):e0226352
pubmed: 31841563
Br J Radiol. 2019 Nov;92(1103):20190660
pubmed: 31538501
Clin Radiol. 2002 Aug;57(8):725-9
pubmed: 12169283
Br J Cancer. 2011 May 24;104(11):1680-5
pubmed: 21540862
Cancer Epidemiol. 2017 Jun;48:140-146
pubmed: 28549339
J Med Screen. 2016 Jun;23(2):89-97
pubmed: 26582492
Breast. 1999 Jun;8(3):116-9
pubmed: 14965726

Auteurs

Marthe Larsen (M)

Section for Breast Cancer Screening, Cancer Registry of Norway, Oslo, Norway.

Marie Lilleborge (M)

Section for Breast Cancer Screening, Cancer Registry of Norway, Oslo, Norway.

Einar Vigeland (E)

Department of Radiology, Vestfold Hospital, Tønsberg, Norway.

Solveig Hofvind (S)

Section for Breast Cancer Screening, Cancer Registry of Norway, Oslo, Norway; Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. Electronic address: solveig.hofvind@kreftregisteret.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH